PHGE BiomX
- 0.4010
- -0.0070-1.72%
BiomX News
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersPredictive Oncology (NASDAQ:POAI) shares rose 36.4% to $1.95 during Tuesday's after-market session. The company's market cap stands at $7.9 million. Brainstorm Cell (NASDAQ:BCLI) shares moved u
BiomX Files to Sell 120.15M Warrants for Holders
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAcrivon Therapeutics (NASDAQ:ACRV) stock rose 12.3% to $10.67 during Wednesday's after-market session. The market value of their outstanding shares is at $329.4 million. Amarin Corp (NASDAQ:AMR
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersImmutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $344.7 million. Syra Health (NASDAQ:SYRA) stock
BiomX to Present Data From Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients With Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
Abstract selected as a "Top Poster", ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GL
HC Wainwright & Co. : The BioMX (PHGE.US) rating was confirmed and adjusted from buy to buy, with a target price of $2.00.
HC Wainwright & Co. : The BioMX (PHGE.US) rating was confirmed and adjusted from buy to buy, with a target price of $2.00.
BiomX's BX211 Phage Therapy: A Revolutionary Approach to Diabetic Foot Osteomyelitis Treatment
Press Release: BiomX Announces the Appointment of Susan Blum to Its Board of Directors
BiomX Announces the Appointment of Susan Blum to its Board of Directors CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "C
BiomX Board Governance Structure and Bylaws Updated
Biomx Inc. at a Crossroads: Shareholder Approval Required for Convertible Securities Amid Liquidity Concerns
BiomX Announces Compliance With NYSE Guidelines on Audit Opinion Disclosure
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific
BiomX Q4 EPS $(0.08) Up From $(0.20) YoY
BiomX (AMEX:PHGE) reported quarterly losses of $(0.08) per share. This is a 60 percent increase over losses of $(0.20) per share from the same period last year.
Analysts Are Bullish on These Healthcare Stocks: BiomX (PHGE), Daré Bioscience (DARE)
Earnings Call Summary | BiomX(PHGE.US) Q4 2023 Earnings Conference
The following is a summary of the BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript:Financial Performance:BiomX reported a decrease in cash balance and short-term deposits from $34.3 million as of 20
BiomX Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
BiomX Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
BiomX's Robust Financial Health and Promising Clinical Advancements Bolster Buy Rating
BiomX's 2023 Cash Balance, Short-Term Deposits And Restricted Cash Of $15.9M And Concurrent $50M Financing Is Expected To Provide Cash Runway Into 2025
BiomX's 2023 Cash Balance, Short-Term Deposits And Restricted Cash Of $15.9M And Concurrent $50M Financing Is Expected To Provide Cash Runway Into 2025
BiomX FY EPS $(0.51) Up From $(0.95) YoY
BiomX (AMEX:PHGE) reported quarterly losses of $(0.51) per share. This is a 46.32 percent increase over losses of $(0.95) per share from the same period last year.
BiomX GAAP EPS of -$0.51
Press Release: BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinica
Analysis
Price Target
No Data
